pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 30 Non-oncology: 20
Oncology: 10
Under Consideration for Negotiation 34 Non-oncology: 21
Oncology: 13
Completed Negotiations 454 With Letter of Intent: 393
Without agreement: 61
Negotiations That Were Not Pursued 85

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Ruzurgi Médunik Canada Inc. Lambert-Eaton myasthenic syndrome (LEMS)
Venclexta AbbVie Corporation in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy
Tecentriq Hoffmann-La Roche For the treatment of the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance Tecentriq should be continued until loss of clinical benefit or un

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Riabni Amgen Canada Inc. Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)
Tecentriq and bevacizumab HOFFMANN-LA ROCHE LIMITED TECENTRIQ (atezolizumab), in combination with AVASTIN (bevacizumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy.
Venclexta AbbVie Corporation Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible
Zolgensma Novartis Pharmaceuticals Canada Inc. Spinal Muscular Atrophy
Calquence ASTRAZENECA CANADA INC Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Calquence ASTRAZENECA CANADA INC Chronic Lymphocytic Leukemia (CLL) (previously untreated): With or without obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) for whom a fludarabine-based regimen is inappropriate
Enerzair Breezhaler Valeo Pharma Inc. Asthma
Atectura Breezhaler Valeo Pharma Inc. Asthma

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
Venclexta AbbVie Corporation Venclexta in combination with low-dose cytarabine is indicated for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy